3/5
08:23 am
vir
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule [Yahoo! Finance]
Medium
Report
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule [Yahoo! Finance]
3/5
08:05 am
vir
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
Low
Report
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
2/28
12:20 am
vir
Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta [Seeking Alpha]
Neutral
Report
Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta [Seeking Alpha]
2/23
01:09 pm
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target raised by analysts at JPMorgan Chase & Co. from $9.00 to $10.00. They now have a "neutral" rating on the stock.
Low
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target raised by analysts at JPMorgan Chase & Co. from $9.00 to $10.00. They now have a "neutral" rating on the stock.
2/23
12:08 pm
vir
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade [Yahoo! Finance]
Low
Report
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade [Yahoo! Finance]
2/23
10:50 am
vir
Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/23
08:15 am
vir
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences [Yahoo! Finance]
Medium
Report
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences [Yahoo! Finance]
2/23
08:05 am
vir
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
High
Report
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
2/22
04:24 pm
vir
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
High
Report
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
2/22
04:05 pm
vir
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
High
Report
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2/20
04:42 pm
vir
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer [Yahoo! Finance]
Low
Report
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer [Yahoo! Finance]
2/20
04:30 pm
vir
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer
Low
Report
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer
2/14
08:03 am
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target raised by analysts at HC Wainwright from $85.00 to $110.00. They now have a "buy" rating on the stock.
Medium
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target raised by analysts at HC Wainwright from $85.00 to $110.00. They now have a "buy" rating on the stock.
2/7
05:22 am
vir
Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Trimmed Their Revenue Forecasts By 11% [Yahoo! Finance]
Low
Report
Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Trimmed Their Revenue Forecasts By 11% [Yahoo! Finance]
2/1
04:05 pm
vir
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
Medium
Report
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
1/31
01:55 pm
vir
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance [Yahoo! Finance]
Low
Report
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance [Yahoo! Finance]
1/29
07:28 am
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $9.00 price target on the stock, down previously from $23.00.
Medium
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $9.00 price target on the stock, down previously from $23.00.
1/23
08:08 am
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target lowered by analysts at HC Wainwright from $95.00 to $85.00. They now have a "buy" rating on the stock.
Low
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target lowered by analysts at HC Wainwright from $95.00 to $85.00. They now have a "buy" rating on the stock.
1/15
01:22 pm
vir
Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why [Yahoo! Finance]
Low
Report
Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why [Yahoo! Finance]